Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

February 1, 2026

Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
DRUG

NRCT-101SR

NRCT-101SR is a sustained release formulation.

Trial Locations (13)

29405

RECRUITING

Coastal Carolina Research Center - North Charleston, North Charleston

30030

RECRUITING

iResearch Atlanta, Decatur

30331

RECRUITING

CenExel ACMR Atlanta Center for Medical Research, Atlanta

31405

RECRUITING

CenExel iRS - iResearch Savannah, Savannah

32751

RECRUITING

Accel Research Sites Network - Maitland, Maitland

33144

RECRUITING

Bio-Medical Research LLC, Miami

33803

RECRUITING

Accel Research Sites - Lakeland Clinical Research Unit, Lakeland

70155

NOT_YET_RECRUITING

DelRicht Research, New Orleans

70769

RECRUITING

DelRicht Research, Prairieville

75115

RECRUITING

Epic Medical Research - DeSoto, DeSoto

89128

RECRUITING

Vector Clinical Trials, Las Vegas

92805

RECRUITING

Advanced Research Center, Inc, Anaheim

02131

RECRUITING

Boston Clinical Trials Llc, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neurocentria, Inc.

INDUSTRY

NCT06215144 - Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD | Biotech Hunter | Biotech Hunter